Finally, another FXR agonist, cilofexor (GS-9674), was evaluated in a non-alcoholic steatohepatitis rat model and was shown to significantly reduce the portal pressure. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.